Skip to content
Menu

Barclays Maintains Equal-Weight on Humacyte, Raises Price Target to $0.6

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Christopher Pasquale maintains Humacyte (NASDAQ:HUMA) with a Equal-Weight and raises the price target from $0.5 to $0.6.

Barclays analyst Christopher Pasquale maintains Humacyte (NASDAQ:HUMA) with a Equal-Weight and raises the price target from $0.5 to $0.6.

Read at benzinga.com